BridgeBio Says Pfizer, Alnylam Aren’t Playing Fair in Blockbuster Race

BridgeBio Pharma Inc. is challenging Pfizer Inc. and Alnylam Pharmaceuticals, Inc. with a heart medicine that it says has better results at a lower cost. But it claims rivals are using questionable tactics to compete in the multibillion-dollar market.

At issue is a video Pfizer presented at a medical meeting this month that claimed its drug, Vyndamax, was “the first and only approved treatment” for a devastating form of heart failure. It left out the fact that BridgeBio’s competing medicine hit the market in November 2024 and Alnylam’s has been available since March. At another recent meeting, Pfizer compared its drug and BridgeBio’s in a manner that wasn’t apples-to-apples, according to BridgeBio Chief Executive Officer Neil Kumar.